Body Awareness Therapy in Peripheral Arterial Disease: A Randomized Controlled Trial.

Pain Manag NursMay 17, 2026 (epub)
Clinical ResearchCardiologyPhysical Medicine & Rehabilitation

Seda Karaca, Emre Şenocak, Mehmet Ali Yürük

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the impact of body awareness therapy (BAT) combined with standard care on patients with peripheral arterial disease (PAD). The study found that the BAT group showed significantly greater improvements in walking performance, muscle strength, body awareness, and self-efficacy compared to the standard care group (p < .001).

Key findings

  • BAT group showed greater improvements in walking performance compared to standard care.
  • Muscle strength increased significantly in the BAT group versus controls.
  • Body awareness and self-efficacy improved more in the BAT group.
  • Pain intensity and psychosocial symptoms improved similarly in both groups.

Why it matters

Incorporating body awareness therapy into standard care may enhance functional rehabilitation for patients with peripheral arterial disease, addressing both physical and psychosocial aspects of their condition.

Source

PubMed · PMID 42144309

Published in Pain Manag Nurs. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.